Genelux Investor Presentation Deck
Phase 1b: Anti-tumor Activity as Monotherapy Leading into Combination
Key Clinical Takeaways
mPFS of 6.1 months
(median 4 prior lines;
95%CI: 2.2-NA) for the six
patients in Cohort 1 virus
monotherapy - the dose
used in Ph2-
SOC-AURELIA
regimen (1-2 prior
lines; mPFS: 6.7 mos)
ELAHARE (1-3 prior
lines; mPFS: 5.62
mos
Cohort 2/3 dosing done
exponentially higher with
no MTD reached.
GENELUX
Lo
Pos
Olvi-Vec Monotherapy
Patient Background & Study Treatment
Heavily pre-treated PRROC patients with documented
progressive disease
Cohort I received a Single cycle of intraperitoneal delivery on
2 consecutive days; total dose: 6x10⁹ pfu, same dose as Phil/III
●
Tolerability:
No Dose Limiting Toxicity (DLT)
No Maximum Tolerated Dose (MTD)
No Grade 4 Adverse Events (AE)
●
Antitumor activity:
Clinical Benefit Rate: 73% (8/11)
4/11 patients had >2x PFS relative to immediate prior
chemotherapy
Translational Evidence:
Activation of tumor-specific T cell response detected in blood
Documented immune activation in tumor microenvironment
with significant influx of TILS
Favorable immune-related genetic signatures
●
●
Manyam et al., Gynecologic Oncology 163 (2021) 481 - 489
11View entire presentation